Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Alabama at Birmingham
About this trial
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
Patients with incomplete treatment and response documentation
Trial population
Patients with diagnosis of Hemophagocytic lymphohistiocytosis (HLH)
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 1 trial groupGroup A: Hemophagocytic lymphohistiocytosis (HLH) Patients
Trial outcomes
Primary outcomes
1
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
Time frame
The participant's survival would be assessed at 180 days from the malignancy diagnosisSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov